| Entries |
| Document | Title | Date |
|---|
| 20080213268 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 09-04-2008 |
| 20080241143 | Inhibition of leukocyte adhesion - This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34. | 10-02-2008 |
| 20080299122 | Modulating immune responses - The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function. | 12-04-2008 |
| 20080299123 | TREATMENT OF CHEMOTHERAPY- OR RADIOTHERAPY-RESISTANT TUMORS - The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy. | 12-04-2008 |
| 20090017029 | Methods and Compositions for Treating Ocular Disorders - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis or AMD. | 01-15-2009 |
| 20090191203 | Bcma Polypeptides And Uses Thereof - The present invention relates to BCMA polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 07-30-2009 |
| 20090191204 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 07-30-2009 |
| 20090220509 | SINGLEC-9 BINDING AGENTS - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 09-03-2009 |
| 20090246200 | Anthrax carbohydrates, synthesis and uses thereof - The present invention presents the isolation, characterization and synthesis of oligosaccharides of | 10-01-2009 |
| 20090280122 | USE OF A VIRUS REGIMEN FOR THE TREATMENT OF DISEASES - The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is described. The virus regimen is applied after reducing, shutting down or modifying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the virotherapy regimen. | 11-12-2009 |
| 20100104572 | METHODS FOR SCREENING FOR THERAPEUTIC MOLECULES AND USE OF THE MOLECULES THEREFROM - The present invention relates in general to the field of cancer diagnostics and treatment. In particular, the present invention provides methods for identifying diagnostic and therapeutic molecules that bind to a carbohydrate antigen on the surface of a cancer cell and induce cell death, to pharmaceutical compositions comprising the molecules and uses thereof. | 04-29-2010 |
| 20100172906 | ANTI-HERPES SIMPLEX VIRUS ANTIBODIES AND METHODS OF USE THEREOF - The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections. | 07-08-2010 |
| 20100178294 | MACROCYCLIC BETA-SECRETASE INHIBITORS - Disclosed are novel compounds of the formula | 07-15-2010 |
| 20100233174 | Anthrax carbohydrates, synthesis and uses thereof - The present invention presents the isolation, characterization and synthesis of oligosaccharides of | 09-16-2010 |
| 20100239584 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X - The present invention relates to compounds derived from sugars which reproduce the epitopes of | 09-23-2010 |
| 20100266596 | THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE - A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease. | 10-21-2010 |
| 20100297128 | GAMMA SECRETASE MODULATORS - This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula [Chemical formula should be inserted here as it appears on abstract in electronic form.] Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I). | 11-25-2010 |
| 20100297129 | METHOD FOR EXTENDING PREGNANCY IN PATIENTS EXHIBITING AT LEAST ONE SYMPTOM OF PREECLAMPSIA AND ECLAMPSIA - A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. | 11-25-2010 |
| 20100297130 | PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR BETA-1,3-GLUCANS - Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with | 11-25-2010 |
| 20110002932 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 01-06-2011 |
| 20110097328 | METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY OF INHIBITORY RNA - The invention provides methods for increasing the activity of an inhibitory RNA (RNAi) in a subject requiring administering one or more poly-ADP-ribose polymerase (PARP) inhibitors and/or one or more PARG activators to the subject. The invention also provides methods for increasing the activity of an inhibitory RNA in a cell or cell population requiring contacting a cell or cell population with one or more PARP inhibitors and/or one or more PARG activators. The invention further provides compositions and kits containing one or more PARP inhibitors and/or one or more PARG activators. | 04-28-2011 |
| 20110097329 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND MODULATING STRESS GRANULE FORMATION - The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors. The invention also provides methods for screening for agents for treating or decreasing the likelihood of developing a stress granule-related disorder or cancer, and methods for determining the propensity for developing a stress granule-related disorder or cancer, as well as compositions and kits containing one or more PARP inhibitors, one or more PARP activators, one or more PARG activators, and one or more ARH3 activators. | 04-28-2011 |
| 20110110948 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L | 05-12-2011 |
| 20110135645 | HUMAN ANTIBODIES NEUTRALIZING HUMAN METAPNEUMOVIRUS - The present invention discloses methods for generating antibodies to human metapneumovirus (HMPV) polypeptides, including antibodies that immunospecifically bind to a HMPV F-protein. The invention also discloses methods for preventing, treating, or ameliorating symptoms associated with HMPV infection. | 06-09-2011 |
| 20110150879 | SPECIFIC DEPLETION OF CD4+ T CELLS - Specific depletion or modulation of activity of CD4 | 06-23-2011 |
| 20110150880 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same. | 06-23-2011 |
| 20110165163 | IDENTIFICATION OF A CONSERVED INNER CORE OLIGOSACCHARIDE OF MORAXELLA CATARRHALIS LIPOPOLYSACCHARIDE AS A VACCINE ANTIGEN - There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium | 07-07-2011 |
| 20110177076 | HUMANIZED ANTI-AMYLOID BETA ANTIBODIES - Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody. | 07-21-2011 |
| 20110206673 | POLYPEPTIDES AND POLYNUCLEOTIDES FOR ARTEMIN AND RELATED LIGANDS, AND METHODS OF USE THEREOF - The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompassed are inhibitors of Artemin and/or related ligands, and uses for these inhibitors. | 08-25-2011 |
| 20110217304 | MONOCLONAL ANTIBODIES DIRECTED TO CD52 - The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described. | 09-08-2011 |
| 20110262441 | METHOD FOR SELECTIVE CONTROL OF HELPER T CELL FUNCTION - The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and/or an anti-allergic action. | 10-27-2011 |
| 20120027762 | IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol (“GPI”) inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by | 02-02-2012 |
| 20120039886 | USE OF AN IMMUNOGLOBULIN G (IGG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES FOR TREATING NEONATAL JAUNDICE CAUSED BY MATERNAL-FOETAL INCOMPATIBILITY WITH RESPECT TO THE ABO SYSTEM - An embodiment relates to the use of an immonuglobulin (IgG) concentrate depleted of anti-A (AcaA) and anti-B (AcaB) antibodies for producing a drug intended for treating neonatal jaundice caused by maternal-fetal incompatibility with respect to the ABO system. | 02-16-2012 |
| 20120039887 | COMPOSITIONS AND METHODS FOR DIAGNOSING PROSTATE CANCER BASED ON DETECTION OF SLC45A3-ELK4 FUSION TRANSCRIPT - RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided. | 02-16-2012 |
| 20120128676 | MUC1 ANTIBODIES - The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer. | 05-24-2012 |
| 20120164145 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE - , one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a α1,6-glucan-containing | 06-28-2012 |
| 20120189632 | METHOD FOR EXTENDING PREGNANCY IN PATIENTS EXHIBITING AT LEAST ONE SYMPTOM OF PREECLAMPSIA AND ECLAMPSIA - A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. | 07-26-2012 |
| 20120294864 | Endoglin Antibodies - The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof. | 11-22-2012 |
| 20130004499 | ANTIBODY AGAINST SEROTYPE E LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-03-2013 |
| 20130004500 | ANTIBODY AGAINST SEROTYPE A LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-03-2013 |
| 20130022602 | METHODS AND COMPOSITIONS TO MODULATE ANTIVIRAL AND IMMUNE ACTIVITY RESPONSES - The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems. | 01-24-2013 |
| 20130022603 | ANTIBODY AGAINST SEROTYPE I LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-24-2013 |
| 20130022604 | ANTIBODY AGAINST SEROTYPE B LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-24-2013 |
| 20130034556 | FREE HEXASACCHARIDE ISOLATED FROM SEVERAL CAMPYLOBACTER SPECIES - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 02-07-2013 |
| 20130034557 | Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use - Cancer-associated O-glycopeptide combination epitopes derived from the VNTR of MUC1 are disclosed. Autoantibodies present in human sera target the combination epitopes and are reduced or absent in cancer patients. The epitopes are useful as therapeutic and immunoprophylactic cancer vaccines. Monoclonal antibodies directed against the epitopes are also useful as immunotherapeutics for treatment and prevention of cancer. Diagnostic methods using the epitopes and antibodies are also disclosed. | 02-07-2013 |
| 20130045207 | ANTIBODY AGAINST SEROTYPE G LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 02-21-2013 |
| 20130078251 | ANTI-MCSP ANTIBODIES - The invention provides anti-MCSP antibodies and methods of using the same. | 03-28-2013 |
| 20130101587 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 04-25-2013 |
| 20130129736 | ASPP2 SPLICING VARIANT - The present invention relates to a method for the in vitro determination of the presence of or a predisposition of a patient to the development of cancer. In the method according to the invention, the presence of a marker is determined in a biological sample of the patient, said marker being selected from a) the amino acid sequence SEQ ID Nr. 2 from the sequence protocol that is provided, or b) a nucleic acid that encodes the amino acid sequence with the SEQ ID Nr. 2. The invention further relates to the amino acid and the encoding nucleic acid and to the use thereof in diagnostics and for molecular therapeutic approaches. | 05-23-2013 |
| 20130171147 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling. | 07-04-2013 |
| 20130195873 | CARBOHYDRATE HAPTEN-BASED ANTI-CANCER VACCINES AND ANTIBODY DRUGS - Immunogenic compositions that contain haptens consisting of carbohydrate moieties are useful to induce an immune response to provide antibodies to epitopes contained in CA215 and also to elicit an immune response to cancers expressing these epitopes. | 08-01-2013 |
| 20130295099 | N-LINKEDGLYCAN COMPOUNDS - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 11-07-2013 |
| 20130295100 | MARKERS FOR ACUTE KIDNEY INJURY AND USES THEREOF - The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury. | 11-07-2013 |
| 20130309237 | Pathogenic Mycobacteria-Derived Mannose-Capped Lipoarabinomannan Antigen Binding Proteins - Described herein are antigen binding proteins that bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM) and methods and kits for using and making the antigen binding proteins. Also described herein are antigen binding proteins that bind to the alpha 1-2 linkage mannose caps of ManLAM, antigen binding proteins that bind to a mannose cap with up to three alpha 1-2 linked mannose residues, and antigen binding proteins that bind to LAM with a mannose sugar capping motif. | 11-21-2013 |
| 20140017247 | COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES - A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment. | 01-16-2014 |
| 20140037633 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same. | 02-06-2014 |
| 20140044721 | ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS - The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors. | 02-13-2014 |
| 20140050731 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 02-20-2014 |
| 20140086923 | Antibodies Directed Against ICOS and Uses Thereof - The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg. | 03-27-2014 |
| 20140154257 | Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents - Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“Fru-AGEs”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-AGEs arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract. Such Fru-AGEs may further interact with moieties of the systemic circulation of those at risk [fructose malabsorbers], i.e. with acute phase proteins, heat shock proteins, immunoglobulins, esRAGE, and sRAGE. Specification describes methods to identify and/or make such excess-free-fructose derived immunogens, i.e. Fru-AGEs, Fru-AGE-haptens, Fru-AGE immune complexes, and to make monoclonal/polyclonal antibodies to such bio-molecules for use as therapeutic agents and/or for use in immuno-assays including fluorescence enzyme immunoassay, microarray specific immunoglobulin/antibody testing, fluids detection [blood and urine] of GI Fru-AGE/haptens/immune-complexes. | 06-05-2014 |
| 20140161806 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA - A specific antibody against a compound of formula (I) | 06-12-2014 |
| 20140170150 | N-LINKED GLYCAN COMPOUNDS - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 06-19-2014 |
| 20140170151 | Synthetic Oligosaccharides for Staphylococcus Vaccine - The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-β-(1→6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-β-(1→6)-glucosamines, such as | 06-19-2014 |
| 20140193416 | OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICLE POLYSACCARIDE PS-I, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS VACCINES AND DIAGNOSTIC TOOLS - The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the | 07-10-2014 |
| 20140234318 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF - The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer. | 08-21-2014 |
| 20140255409 | METHOD FOR EXTRACORPOREAL ELIMINATION OF ONE OR MORE COMPONENTS FROM BLOOD - A method for extracorporeal elimination of one or more components from blood where whole blood or blood plasma is added to a blood treatment device containing an adsorbent which binds the one or more components is disclosed. The adsorbent comprises at least one matrix to which at least one ligand having specific binding affinity to said one or more component is covalently bound. The ligand comprises a glycosidically bound aglycon and at least one saccharide, preferably blood group determinant A, blood group determinant B, blood group H determinant, a P antigen, or a Pk antigen; or said ligand is an amino acid, a peptide or an antibody. Methods for treatment of transplant recipients, and to use a blood treatment device is also disclosed. | 09-11-2014 |
| 20140294840 | EXPRESSION OF MIRNAS IN PLACENTAL TISSUE - Provided are human miRNAs associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said miRNAs may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations. In addition, new pharmaceutical and diagnostic compositions for use in diagnosis and therapy of said disorders are described. | 10-02-2014 |
| 20140328847 | MITIGATION OF DISEASE BY INHIBITION OF GALECTIN-12 - It has now been discovered that mice with an ablated galectin-12 gene exhibit enhanced fat mobilization (lipolysis), have reduced adipose tissue mass, improved insulin sensitivity and glucose tolerance, and increased mitochondrial respiration. Inhibition of galectin-12 activity can therefore be used to reduce, mitigate, inhibit and/or prevent obesity, type 2 diabetes, metabolic diseases, mitochondrial diseases, other disease conditions associated with and/or caused by the abnormal expression or overexpression of galectin-12, and other disease conditions with normal galectin-12 expression but will benefit from galectin-12 inhibition. | 11-06-2014 |
| 20140341908 | METHODS AND COMPOSITIONS TO MODULATE ANTIVIRAL AND IMMUNE ACTIVITY RESPONSES - The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems. | 11-20-2014 |
| 20140341909 | CONJUGATION OF BIOMOLECULES USING DIELS-ALDER CYCLOADDITION - A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents. | 11-20-2014 |
| 20140356367 | MONOPHOSPHORYLATED LIPID A DERIVATIVES - The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided. | 12-04-2014 |
| 20140363436 | DIAGNOSING AND TREATING IGA NEPHROPATHY - Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject. | 12-11-2014 |
| 20140363437 | COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT - A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10 | 12-11-2014 |
| 20150023968 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING HYPERTHYROIDISM IN COMPANION ANIMALS - An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula. | 01-22-2015 |
| 20150044218 | N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF - The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer. | 02-12-2015 |
| 20150050282 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X - The present invention relates to compounds derived from sugars which reproduce the epitopes of | 02-19-2015 |
| 20150086555 | Anti-Hemagglutinin Antibody Compositions and Methods of Use Thereof - The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection. | 03-26-2015 |
| 20150093388 | Antibodies and Assays for Detection of Folate Receptor 1 - The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided. | 04-02-2015 |
| 20150110790 | COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES - A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment. | 04-23-2015 |
| 20150125451 | COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY - This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody. | 05-07-2015 |
| 20150139998 | NOVEL CELL WALL POLYMERS OF ENTEROCOCCUS FAECALIS AND USES THEREOF - The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection. | 05-21-2015 |
| 20150147328 | VACCINE COMPOSITION FOR PREVENTING STAPHYLLOCOCCUS AUREUS INFECTION - The present invention relates to a vaccine composition for preventing | 05-28-2015 |
| 20150322138 | MDR E. COLI SPECIFIC ANTIBODY - The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) | 11-12-2015 |
| 20150335709 | Colostrum Composition Enriched in Anti-Endotoxin Antibodies - The present invention provides a colostrum formulation enriched in broadly cross-reactive anti-endotoxin antibodies. Further provided is a method for reducing endotoxemia and blocking the onset of sepsis in patients comprising administering to the patients a colostrum formulation enriched with anti-endotoxin antibodies. Further provided is a method for treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome, comprising the step of administering to the patient an effective amount of the composition of the present invention. | 11-26-2015 |
| 20150368340 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF - Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject. | 12-24-2015 |
| 20160000914 | COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER - The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations. | 01-07-2016 |
| 20160003839 | THE DETECTION OF FREE AND PROTEIN-BOUND NON-HUMAN GAL-ALPHA(1-3)-GAL EPITOPE - The present invention relates to the provision of antibody fragments capable of binding selectively to the Gal-α-(1→3)-Gal epitope. The invention further relates to assay systems comprising these antibody fragments for use in testing transplantation tissue for possible rejection complications. This epitope is often found on porcine tissue destined for human transplantation. The epitope is also found on biopharmaceuticals and on some infectious agents and accordingly the invention also provides assay systems for these applications. | 01-07-2016 |
| 20160017062 | ANTIBODIES TARGETED TO FUNGAL CELL WALL POLYSACCHARIDES - A compound comprising one or more polysaccharide moieties each independently represented by the formula β(1→4)-[GlcNH—R] | 01-21-2016 |
| 20160024222 | MONOCLONAL ANTIBODIES AGAINST ANTITHROMBIN B - This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (ATβH). These ATβH binding proteins can block the anti-coagulant activity of ATβ to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies. | 01-28-2016 |
| 20160031989 | Methods for Promoting Reinnervation of Auditory Hair Cells - This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin. | 02-04-2016 |
| 20160068608 | TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER - An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described. | 03-10-2016 |
| 20160068611 | MONOCLONAL ANTIBODY RECOGNIZING SIALYLATED SUGAR CHAINS - The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Siaα2,6Galβ1,4GlcNAc (6′-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Galβ1,4GlcNAc”, “Siaα2,3Galβ1,4GlcNAc”, or “Siaα2,6Galβ1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH | 03-10-2016 |
| 20160130356 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE - The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease. | 05-12-2016 |
| 20160137724 | ANTIBODIES FOR PREVENTION AND TREATMENT OF DISEASES CAUSED BY CLOSTRIDIUM DIFFICILE - The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the | 05-19-2016 |
| 20160376376 | Novel Method of Targeting Glycoproteins to Treat Cancer - The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated O-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth. For example, monoclonal antibody AR9.6 may be used to target truncated O-glycans on the MUC16 glycoprotein, thereby inhibiting the phosphatidyiinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway. | 12-29-2016 |
| 20190142921 | COMPOSITIONS AND METHODS FOR THE EXPRESSION OF EUKARYOTIC OLIGOSACCHARIDES ON BACTERIAL OUTER MEMBRANE VESICLES | 05-16-2019 |
